Development and Evaluation of Guaifenesin Bilayer Tablet
DOI:
https://doi.org/10.37285/ijpsn.2010.3.3.10Abstract
The objective of the present research was to develop a Bilayer tablet of guaifenesin (GBT) using superdisintegrant MCC and sodium starch glycolate for the fast release layer and metalose 90 SH and carbopol 934 for the sustaining layer. The guaifenesin SR granules of different formulation were evaluated for bulk density, tapped density, angle of repose, Carr’s index and Hausners ratio and results were found to be 0.460 ± 0.12 to 0.515 ± 0.03 gm/cm3 , 0.550 ±0.03 to 0.590 ±0.04 gm/cm3 , 19 ±0.01 to 26 ± 0.23, 13.72 ± 0.03 to 19.56 ± 0.04 & 1.137 to 1.196, respectively. The prepared bilayer tablets were evaluated for weight variation, hardness, friability, drug content and in vitro drug release. In vitro dissolution studies were carried out in a USP 24 apparatus I. The formulations gave an initial burst effect to provide the loading dose of the drug followed by sustained release for 12 h from the sustaining layer of matrix embedded tablets. In vitro dissolution kinetics followed the Higuchi model via a non-Fickian diffusion controlled release mechanism after the initial burst release. Stability studies conducted for optimized formulation did not show any change in physical appearance, drug content, matrix integrity and in vitro drug release. The results of the present study clearly indicated that GBT was a stable dosage form and a promising potential of the guaifenesin bilayer system as an alternative to the conventional dosage forms
Downloads
Metrics
Keywords:
GBT, Guaifenesin, Bilayer, immediate release, control release
Downloads
Published
How to Cite
Issue
Section
References
sustained release tablets using insoluble matrix system. Indian J. Pharm. Sci. 59: 312–315 (1997)
Acevez JM, Cruz R and Hernandes E. Preparation and characterization of furosemide-Eudragit controlled release system. Int. J. Pharm. 195: 101-108 (2000)
Ansel HC, Allen LV and Popovich NG, Capsules and Tablets, in Pharmaceutical Dosage Formsand Drug Delivery Systems, 7th ed., Lippincott Williams &Wilkins, Philadelphia 2002
Bennett S, Hoffman N and Monga M. "Ephedrine- and guaifenesin-induced nephrolithiasis". J Altern Complement Med 10: 967–969 (2004)
Bourne DW, Pharmacokinetics, Modern Pharmaceutics, Marcel Dekker, New York 2002.
Brabander CD, Vervaet C and Remon JP. Development and Evaluation of sustained release matrix tablet. J.Controlled Release. 77: 245-254 (2002).
Check JH, Adelson HG and Wu CH. Improvement of cervical factor with guaifenesin. Fertil. Steril. 37: 707-708 (1982)
Cobby J, Mayersohn M, and Walker GC. Influence of shape factors on kinetics of drug release from matrix tablets. II. Experimental. J. Pharm. Sci. 63:732-737 (1974)
Costa P and Labo JSMS. Modelling and comparison of dissolution profiles. Eur. J. Pharm. Sci. 13: 123–133 (2001)
Guyot M and Fawaz F. Nifedipine loaded polymeric microspheres: preparation and physical characteristics, Int. J. Pharm. 175: 61–74 (1998)
Harland RS, Gazzaniga A., Sangalli ME, Colombo P, and Peppas NA. Drug/polymer matrix swelling and dissolution. Pharm. Res. 5:488-494 (1988).
Higuchi F, Seta Y, Otsuka T, Nishimura K, Okada R and Koike H. Preparation and pharmacological evaluation of captopril sustained release dosage forms using oily semisolid matrix. Int. J. Pharm. 41: 255–262 (1988)
Higuchi T. Mechanism of sustained action medication, J. Pharm. Sci. 52: 1145–1149 (1963)
Higuchi T. Rate of release of medicaments from ointment bases containing drugs in suspension. J. Pharm. Sci. 50: 874-875 (1961)
Korsmeyer RW, Gurny R, Doelker E, Buri P and Peppas NA. Mechanism of solute release from hydrophilic polymers, Int. J. Pharm. 15: 25–35 (1983)
Makhija SN and Vavia PR. Once daily sustained release tablets of venlafaxine, a novel antidepressant. Eur. J. Pharm. Biopharm. 54: 9–15 (2002)
Martin A, Bustamante P and Chun A. Micromeritics, Physical Pharmacy-Physical Chemical Principles in the Pharmaceutical Sciences, Lippincott Williams and Wilkins, Baltimore 2002.
Mathews BR. Regulatory aspects of stability testing in Europe, Drug Dev. Ind. Pharm. 25: 831–856 (1999)
Merchant HA, Shoaib HM, Tazeen J and Yousuf RI. Once-daily tablet formulation and in vitro release evaluation of cefpodoxime using hydroxypropyl methylcellulose: A technical note. AAPS Pharm. Sci. Tech. 7: 1028 -1037 (2006)
Pather I, Russell I, Syce JA and Neau SH. Sustained release theophylline tablets by direct compression, Part 1: formulation and in vitro testing. Int. J. Pharm. 164: 1–10 (1998)
Peppas NA. Analysis of Fickian and non Fickian drug release from polymers, Pharm. Acta Helv. 60: 110–111 (1985)
Rahman Z, Ali M and Khar RK.Design and evaluation of bilayer floating tablets of captopril. Acta Pharm. 56: 49–57 (2006)
Rawlins EA. Formulation, in Bentley’s Text Book of Pharmaceutics, Bailliere Tindall,
London 1996
Sharma S, Praveen S, Shraddha B, and Pawar AP. Adsorption of Meloxicam on Porous Calcium Silicate: Characterization and tablet formulation. AAPS PharmSciTech. 6: 618-625 (2005).
Staniforth J. Powder Flow, in Pharmaceutics – the Science of Dosage Form Design, Churchill Livingstone, London 2002.
Thummel KE, Shen DD, Isoherranen N and Smith HE, Design and Optimization of Dosage Regimens; Pharmacokinetic Data, Goodman and Gilman’s The Pharmacological Basis of Therapeutics, McGraw-Hill Medical Publishing Division, London 2006.
USP 24/NF 19, USP Convention, Rockville 1999.
Uzdemir N, Ordu S and Ozkan Y. Studies of floating dosage forms of furosemide: in vitro and in vivo evaluation of bilayer tablet formulations, Drug Dev. Ind. Pharm. 26: 857–866 (2000)
Wagner JG. Interpretation of percent dissolved-time plots derived from in vitro testing of conventional tablets and capsules, J. Pharm. Sci. 58: 1253–1257 (1969).
